Progenitor (PGEN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progenitor (PGEN)

PGEN 4.145

+2.6%

3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (58)	3/21/1998 1:10:00 AM
From: Czechsinthemail	Read Replies (2) of 106

3/20/98 Shares Of Progenitor Soar As Research Boosts Gene-Therapy Claim MENLO PARK, Calif. -(Dow Jones)- Shares of Progenitor Inc. soared Friday after the company said published research suggests its nonviral gene-therapy system may be effective in treating solid-tumor cancers. At the close, shares of Progenitor (PGEN) were up 50 cents, or 27%, at $2.375, on Nasdaq volume of about 1.5 million, compared with the daily average of 30,000 shares. Progenitor said its researchers, in collaboration with others, showed its T7T7 gene therapy was effective in shrinking tumors in six out of 10 mice injected with the drug. The mice were also receiving the antiviral drug ganciclovir. Full, permanent tumor regression was achieved in three of the six tumors. The findings appeared in Friday's issue of Human Gene Therapy. The company said it is now working to develop gene treatments for blood-vessel damage or ischemia in cardiovadcular disorders. Progenitor went public in October. It was previously 80% owned by Interneuron Pharmaceuticals Inc.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next